AstraZeneca

ASTRAZENECA NEWSROOM (7 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012

AstraZeneca, Acerta Pharma, MedImmune to present at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego

PRESS RELEASE -- 29, November 2018

27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio … Read the full press release →

AstraZeneca enters into an agreement with Covis Pharma to sell its rights to Alvesco, Omnaris and Zetonna

PRESS RELEASE -- 7, November 2018

CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with … Read the full press release →

AstraZeneca and Amgen announce US FDA Breakthrough Therapy Designation for tezepelumab in patients with severe asthma

PRESS RELEASE -- 12, September 2018

AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release →

AstraZeneca and Merck & Co., Inc. announce positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets

PRESS RELEASE -- 28, June 2018

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release →

AstraZeneca and MedImmune present results from Phase III clinical trial of moxetumomab pasudotox in patients with hairy cell leukaemia

PRESS RELEASE -- 4, June 2018

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission … Read the full press release →

AstraZeneca: US FDA approval for Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer

PRESS RELEASE -- 22, February 2018

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release →

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

PRESS RELEASE -- 22, January 2018

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release →